Background
Jade Teakell
Shedding Light on the Dense Matter of C3 ...

This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.

Shedding Light on the Dense Matter of C3 Glomerulopathy
Background
swapnil hiremath
Healing, Hype, or Harm: The NefIgArd trial

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

Healing, Hype, or Harm: The NefIgArd trial
Background
Cristina Adriana Popa
PRAECISely Predicting Preeclampsia

This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.

PRAECISely Predicting Preeclampsia
Background
swapnil hiremath
The Worldwide Shadow of Kidney Disease

This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.

The Worldwide Shadow of Kidney Disease
Background
swapnil hiremath
The PROTECT-V platform - RENALISM no more?

This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.

The PROTECT-V platform - RENALISM no more?

roxadustat

The Dual Dustat Visual abstracts

UPDATE:

On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.

The Incident dialysis visual abstract has been updated to reflect this change.

At their first attempt, the NSMC interns Alicja Rosolowska and Keia Sanderson have created beautiful visual abstract


The Roxadustat Chronicles: A Two-Article NephJC

The Roxadustat Chronicles: A Two-Article NephJC

The HIF inhibitor trials were announced almost a year and half ago at KidneyWk 2019. We are finally seeing the trials get published. Here are the first two, a sub-group analysis of three dialysis studies focused on incident dialysis patients and a placebo controlled pre-dialysis study.